|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
2
|
Asamura H, Goya T, Koshiishi Y, et al;
Japanese Joint Committee of Lung Cancer Registry. A Japanese Lung
Cancer Registry study: prognosis of 13,010 resected lung cancers. J
Thorac Oncol. 3:46–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paik PK, Johnson ML, D’Angelo SP, Sima CS,
Ang D, Dogan S, Miller VA, Ladanyi M, Kris MG and Riely GJ: Driver
mutations determine survival in smokers and never-smokers with
stage IIIB/IV lung adenocarcinomas. Cancer. 118:5840–5847. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Suda K, Tomizawa K and Mitsudomi T:
Biological and clinical significance of KRAS mutations in lung
cancer: an oncogenic driver that contrasts with EGFR mutation.
Cancer Metastasis Rev. 29:49–60. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Munfus-McCray D, Harada S, Adams C, Askin
F, Clark D, Gabrielson E and Li QK: EGFR and KRAS mutations in
metastatic lung adenocarcinomas. Hum Pathol. 42:1447–1453. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hung JJ, Jeng WJ, Hsu WH, Wu KJ, Chou TY,
Hsieh CC, Huang MH, Liu JS and Wu YC: Prognostic factors of
postrecurrence survival in completely resected stage I non-small
cell lung cancer with distant metastasis. Thorax. 65:241–245. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakagawa T, Okumura N, Ohata K, Igai H,
Matsuoka T and Kameyama K: Postrecurrence survival in patients with
stage I non-small cell lung cancer. Eur J Cardiothorac Surg.
34:499–504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugimura H, Nichols FC, Yang P, Allen MS,
Cassivi SD, Deschamps C, Williams BA and Pairolero PC: Survival
after recurrent nonsmall-cell lung cancer after complete pulmonary
resection. Ann Thorac Surg. 83:409–418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Williams BA, Sugimura H, Endo C, Nichols
FC, Cassivi SD, Allen MS, Pairolero PC, Deschamps C and Yang P:
Predicting postrecurrence survival among completely resected
nonsmall-cell lung cancer patients. Ann Thorac Surg. 81:1021–1027.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hung JJ, Hsu WH, Hsieh CC, Huang BS, Huang
MH, Liu JS and Wu YC: Post-recurrence survival in completely
resected stage I non-small cell lung cancer with local recurrence.
Thorax. 64:192–196. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kosaka T, Yatabe Y, Onozato R, Kuwano H
and Mitsudomi T: Prognostic implication of EGFR, KRAS, and TP53
gene mutations in a large cohort of Japanese patients with
surgically treated lung adenocarcinoma. J Thorac Oncol. 4:22–29.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Katayama T, Matsuo K, Kosaka T, Sueda T,
Yatabe Y and Mitsudomi T: Effect of gefitinib on the survival of
patients with recurrence of lung adenocarcinoma after surgery: a
retrospective case-matching cohort study. Surg Oncol. 19:e144–e149.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu HP, Isaac Wu HD, Chang JW, Wu YC, Yang
HY, Chen YT, Hsieh WY, Chen YT, Chen YR and Huang SF: Prognostic
implications of epidermal growth factor receptor and KRAS gene
mutations and epidermal growth factor receptor gene copy numbers in
patients with surgically resectable non-small cell lung cancer in
Taiwan. J Thorac Oncol. 5:1175–1184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim YT, Kim TY, Lee DS, Park SJ, Park JY,
Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, et al: Molecular changes
of epidermal growth factor receptor (EGFR) and KRAS and their
impact on the clinical outcomes in surgically resected
adenocarcinoma of the lung. Lung Cancer. 59:111–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyamae Y, Shimizu K, Mitani Y, et al:
Mutation detection of epidermal growth factor receptor and KRAS
genes using the smart amplification process version 2 from
formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn.
12:257–264. 2010. View Article : Google Scholar
|
|
16
|
Araki T, Shimizu K, Nakamura K, et al:
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification
process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon
12 mutations in lung adenocarcinoma: comparison of PNA-clamp
SmartAmp2 and PCR-related methods. J Mol Diagn. 12:118–124. 2010.
View Article : Google Scholar
|
|
17
|
Kakegawa S, Shimizu K, Sugano M, Miyamae
Y, Kaira K, Araki T, Nakano T, Kamiyoshihara M, Kawashima O and
Takeyoshi I: Clinicopathological features of lung adenocarcinoma
with KRAS mutations. Cancer. 117:4257–4266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hung JJ, Jeng WJ, Hsu WH, Huang BS and Wu
YC: Time trends of overall survival and survival after recurrence
in completely resected stage I non-small cell lung cancer. J Thorac
Oncol. 7:397–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnson ML, Sima CS, Chaft J, Paik PK, Pao
W, Kris MG, Ladanyi M and Riely GJ: Association of KRAS and EGFR
mutations with survival in patients with advanced lung
adenocarcinomas. Cancer. 119:356–362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Endo C, Sakurada A, Notsuda H, Noda M,
Hoshikawa Y, Okada Y and Kondo T: Results of long-term follow-up of
patients with completely resected non-small cell lung cancer. Ann
Thorac Surg. 93:1061–1068. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hotta K, Kiura K, Toyooka S, Takigawa N,
Soh J, Fujiwara Y, Tabata M, Date H and Tanimoto M: Clinical
significance of epidermal growth factor receptor gene mutations on
treatment outcome after first-line cytotoxic chemotherapy in
Japanese patients with non-small cell lung cancer. J Thorac Oncol.
2:632–637. 2007. View Article : Google Scholar
|
|
22
|
Kalikaki A, Koutsopoulos A, Hatzidaki D,
Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V
and Voutsina A: Clinical outcome of patients with non-small cell
lung cancer receiving front-line chemotherapy according to EGFR and
K-RAS mutation status. Lung Cancer. 69:110–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takano T, Fukui T, Ohe Y, Tsuta K,
Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K
and Tamura T: EGFR mutations predict survival benefit from
gefitinib in patients with advanced lung adenocarcinoma: a
historical comparison of patients treated before and after
gefitinib approval in Japan. J Clin Oncol. 26:5589–5595. 2008.
View Article : Google Scholar
|
|
24
|
Toyooka S, Takano T, Kosaka T, et al:
Epidermal growth factor receptor mutation, but not sex and smoking,
is independently associated with favorable prognosis of
gefitinib-treated patients with lung adenocarcinoma. Cancer Sci.
99:303–308. 2008. View Article : Google Scholar
|
|
25
|
Sonobe M, Kobayashi M, Ishikawa M, et al:
Impact of KRAS and EGFR gene mutations on recurrence and survival
in patients with surgically resected lung adenocarcinomas. Ann Surg
Oncol. 19(Suppl 3): S347–S354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guan JL, Zhong WZ, An SJ, et al: KRAS
mutation in patients with lung cancer: a predictor for poor
prognosis but not for EGFR-TKIs or chemotherapy. Ann Surg Oncol.
20:1381–1388. 2013. View Article : Google Scholar : PubMed/NCBI
|
